Eli Lilly and Company (LLY)

NYSE
Currency in USD
Disclaimer
340.73
+1.05
(+0.31%)
Closed
342.29
+1.56
(+0.46%)
After Hours
Real-time Data
Day's Range
337.82
342.87
52 wk Range
231.87
384.44
Volume
2,288,052
Prev. Close
339.68
Open
338.56
Day's Range
337.82-342.87
52 wk Range
231.87-384.44
Volume
2,288,052
Average Volume (3m)
2,895,518
1-Year Change
39.47%
Shares Outstanding
950,177,900
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
388.40
Upside +13.99%

People Also Watch

407.69
DE
-0.45%
110.79
COP
-1.10%

Eli Lilly and Company News

Eli Lilly and Company Analysis

Eli Lilly and Company Company Profile

Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.

Employees
35000